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Abstract
Diabetes mellitus (DM) is characterized by hyperglycemia caused by a lack of insulin, insulin resistance, or both. There is
increasing evidence that insulin also plays a role in Alzheimer’s disease (AD) as it is involved in the metabolism of b-amyloid
(Ab) and tau, two proteins that form Ab plaques and neurofibrillary tangles (NFTs), respectively, the hallmark lesions in AD.
Here, we examined the effects of experimental DM on a pre-existing tau pathology in the pR5 transgenic mouse strain that
is characterized by NFTs. pR5 mice express P301L mutant human tau that is associated with dementia. Experimental DM was
induced by administration of streptozotocin (STZ), which causes insulin deficiency. We determined phosphorylation of tau,
using immunohistochemistry and Western blotting. Solubility of tau was determined upon extraction with sarkosyl and
formic acid, and Gallyas silver staining was employed to reveal NFTs. Insulin depletion by STZ administration in six months-
old non-transgenic mice causes increased tau phosphorylation, without its deposition or NFT formation. In contrast, in pR5
mice this results in massive deposition of hyperphosphorylated, insoluble tau. Furthermore, they develop a pronounced
tau-histopathology, including NFTs at this early age, while the pathology in sham-treated pR5 mice is moderate. Whereas
experimental DM did not result in deposition of hyperphosphorylated tau in non-transgenic mice, a predisposition to
develop a tau pathology in young pR5 mice was both sufficient and necessary to exacerbate tau deposition and NFT
formation. Hence, DM can accelerate onset and increase severity of disease in individuals with a predisposition to
developing tau pathology.
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Introduction
Alzheimer’s disease (AD) is a devastating progressive neurode-
generative disease affecting more than 15 million people
worldwide [1]. It is characterized by neuronal loss associated with
a progressive decline in memory and other cognitive functions,
resulting in dementia. Frontotemporal lobar degeneration (FTLD)
is the second most common form of dementia presenting before
the age of 65 [2,3]. FTLD is a heterogeneous group of
neurodegenerative disorders that is characterized clinically by
either behavioural changes, such as in personality and social
conduct; and/or language abnormalities, such as aphasia [4].
In the AD brain, the b-amyloid (Ab) peptide and the
microtubule-associated protein tau undergo changes in their
tertiary structures leading to self-association and deposition. Ab
is derived from the precursor protein APP and forms the major
constituent of plaques; while hyperphosphorylated forms of tau are
the major constituents of neurofibrillary tangles (NFTs) [5]. Tau
contains multiple phosphorylation sites, that are hyperphosphory-
lated under pathological conditions, such as AD and FTLD [6].
Deposition of hyperphosphorylated tau in the absence of an overt
Ab pathology characterizes approximately half of all FTLD cases
[2]. In Frontotemporal dementia with parkinsonism linked to
chromosome 17 (FTDP-17), a subtype of FTLD, mutations were
identified in the tau-encoding gene MAPT, such as P301L [7,8].
We, along with others, expressed mutant human tau in transgenic
mice that recapitulate major aspects of the human disease
(reviewed in [9]).
Diabetes mellitus (DM) is characterized by hyperglycemia. In
type 1 diabetes (insulin-dependent diabetes mellitus (IDDM)), this
results from an absolute deficiency of insulin secretion [10]. In type
2 diabetes (non-insulin-dependent diabetes mellitus (NIDDM))
both insulin resistance of target organs and inadequate insulin
secretion cause hyperglycemia [10]. DM is associated with
pathological changes in numerous peripheral organs, such as eyes,
kidneys and peripheral nerves, but it also affects the central
nervous system (CNS). Specifically, learning abilities are impaired
and memory deficits are evident in both types of diabetes [11]. A
common feature of AD and DM is amyloid deposition in target
organs; Ab and tau in AD brains, and amylin in pancreatic islets of
type 2 diabetes [12]. Amidst some controversy, there is growing
evidence that having DM almost doubles the risk to develop AD,
with biochemical analysis supporting a link between AD and
insulin dysfunction [13]. Defective insulin signalling and altered
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Furthermore, insulin can modulate tau phosphorylation in vitro
[17] and in non-transgenic mice, depletion of insulin results in
increased tau phosphorylation, with no concomitant formation of
pathological tau deposits [18,19]. While co-morbidity is difficult to
address in humans, transgenic mice offer the selective advantage to
determine whether reduction in insulin levels can exacerbate a
pre-existing tau pathology.
Here, we examined the effects of STZ-induced insulin depletion
on the onset and progression of tau pathology in young pre-
symptomatic transgenic mice (pR5) that express human tau in
neurons together with the pathogenic P301L mutation. Insulin
deficiency and consequently, increased glucose levels exacerbated
the histopathology of pR5, with accelerated tau deposition and
NFT formation.
Results
Lack of insulin has previously been shown to result in increased
phosphorylation of tau in non-transgenic mice, but failed to induce
NFT formation [18,19]. Here, we hypothesized that depletion of
insulin may accelerate the tau pathology in a mouse model that is
prone to develop NFTs. Therefore, we treated P301L tau
transgenic (pR5) and wild-type mice as controls with STZ at 4
months of age, 2 months before NFT formation is initiated in
P301L tau mice. As expected, the STZ treatment caused
persistently increased blood glucose levels as pancreatic b-cells in
the islets of Langerhans were destroyed resulting in depletion of
systemic insulin (Figure 1A). Islets of pR5 mice were indistin-
guishable from those of wild-type mice, as revealed by hematox-
ylin/eosin staining and immunohistochemistry with antibodies to
insulin and glucagon (Figure 1B,C). Accordingly, serum insulin
levels of pR5 and wild-type mice were similar (0.7960.18 ng/ml
(pR5) versus 0.8360.17 ng/ml (wild-type), n=8). In contrast,
insulin-positive b-cells were absent from islets of STZ-treated pR5
and wild-type mice, while glucagon-secreting a-cells were not
affected (Figure 1C).
To determine the effects of STZ-induced DM on the
phosphorylation of tau, we performed an immunohistochemical
analysis of brain sections at 6 months of age, using phosphory-
lation- and site-specific antibodies (Table 1). NFT formation in
pR5 mice is initiated at 6 months of age [20]. Consistent with our
previous findings [20,21], sham-treated pR5 mice presented with a
moderate tau pathology, including phosphorylation at the S202/
T205 epitope (AT8), whereas other more pathogenic sites, such as
S422 (PS422) revealed no marked phosphorylation (Figure 2).
AT8-positive neurons were mainly found in the amygdala, in line
with the previous finding that the tau pathology in the pR5 strain
is initially restricted to the amygdala, a site where NFTs form
when the mice age [22,23]. Compared to sham-treated pR5 mice,
in STZ-treated mice, more neurons in the amygdala stained
positive for AT8. Importantly and different from sham treated
controls, most of the AT8-positive neurons in STZ-treated pR5
mice also stained with the pS422 antibody, suggesting a more
advanced pathology. Accordingly, numbers of AT8 and PS422
double positive cells were significantly increased in STZ-treated
compared to sham-injected pR5 mice. Furthermore, dystrophic
neurites were visualized with AT8 and pS422 in STZ-treated pR5
brains, but only with AT8 in sham-treated pR5 mice. Taken
together, STZ-induced DM in pR5 mice resulted in an increased
phosphorylation of tau, in particular at the pathogenic site pS422.
In disease, progressive hyperphosphorylation of tau, in partic-
ular at pathologic sites, such as pS422 occurs as disease progresses,
concomitant with NFT formation [6]. The abundant phosphor-
Figure 1. Effects of streptozotocin (STZ) administration in
mice. (A) STZ injection in both 4 months old wild-type (WT) and pR5
mice induces chronically high blood glucose levels, while levels in
sham-injected WT and pR5 control mice are normal (n=12). Blood
glucose levels remained high until mice were analyzed at 6 months of
age. (B) Hematoxylin/eosin staining and (C) immunofluorescence
staining with insulin- (green) and glucagon-specific (red) antibodies of
pancreatic islets of Langerhans reveals comparable islet architecture in
6 months old sham-injected WT and pR5 mice. However, insulin
producing b-cells are absent from both WT and pR5 islets 60 days after
STZ administration, whereas glucagon secreting a-cells remained.
Nuclei were counterstained with DAPI (blue). Scale bar, 25 mm.
doi:10.1371/journal.pone.0007917.g001
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administration indicated that more NFTs may have been induced
by the STZ treatment than are normally found at this age [20]. To
address this, we used Gallyas silver impregnation that reveals
filamentous tau deposits (Figure 3). As expected, NFTs were
hardly ever found in sham-injected pR5 mice and completely
absent in non-transgenic controls. In contrast, STZ-treated pR5
brains showed significant numbers of Gallyas-positive NFTs in the
amygdala. Furthermore, dystrophic neurites were Gallyas-positive
in STZ-treated, but not sham-treated pR5 brains. Taken together,
Gallyas silver staining revealed advanced deposition of fibrillar tau
in STZ-treated pR5 mice.
To rule out that STZ administration may have altered
expression level or pattern of transgenic tau, we performed
immunohistochemistry of brain sections and Western blotting of
brain extracts, using phosphorylation-independent tau specific
antibodies, HT7 and TAU5. We found that STZ treatment did
not affect expression levels of transgenic tau in pR5 mice as there
were no significant differences in STZ- injected compared to
sham-treated pR5 mice (Figure 4).
Next, we addressed the solubility of tau, using RAB, RIPA and
formic acid (FA) sequential extractions [24,25], to determine levels
of insolubleaggregatesand phosphorylationof tau inbrains ofSTZ-
treated pR5 and wild-type mice. These experiments were
complemented by a second protocol for the isolation of insoluble
tau using sarkosyl extraction [26,27]. Proteins from both extraction
procedures were analyzed by Western blotting, using both
phosphorylation-dependent and -independent antibodies (Table 1).
We found that STZ administration in non-transgenic mice resulted
in increased phosphorylation of endogenous murine tau at multiple
sites, including T181 (AT270), AT8, T212/S214 (AT100), S262/
S356 (12E8), S396/S404 (PHF-1) and, to a much lesser degree,
pS422intheRABfractionoftheamygdalahomogenate(Figure5A).
Although, slightly increased amounts of tau were found in the RIPA
fractionof STZ-treatednon-transgenicmice comparedto untreated
controls, suggesting a decreased solubility of murine tau, no tau was
revealed in the corresponding FA fractions of STZ-treated non-
transgenicmice(Figure 5B and C).Similarly, murine tau wasabsent
from sarkosyl-insoluble extracts of STZ treated non-transgenic
brains (data not shown). Hence, insulin depletion induced tau
hyperphosphorylation without formation of detectable insoluble
deposits in non-transgenic mice.
In comparison, in 6 months-old sham-treated pR5 mice, both
endogenous murine and transgenic human tau was phosphorylated
at multiple sites including AT8, AT270, AT100, 12E8, PHF-1 and
PS422 (Figure 5A). While both transgenic human and endogenous
murine tau was readily detectable in these sham-treated pR5 in the
RAB and RIPA fractions, as revealed by antibodies HT7 and tau-5,
tau was absent from FA fractions (Figure 5C), and hardly detectable
in the sarkosyl-insoluble fraction (Figure 5D). Hence, 6 months-old
pR5 mice are at an age before the onset of an overt tau pathology.
However upon STZ treatment, levels of RIPA-soluble transgenic
and endogenous tau markedly increased, as revealed by HT7 and
tau-5 (Figure 5A and B). Most importantly, HT7 and tau-5 revealed
a strong signal for tau in the FA fractions of STZ-treated pR5 mice
(Figure 5C). Similarly, there were significant amounts of sarkosyl-
insoluble tau in these mice (Figure 5D). Despite reduced levels of
RAB soluble transgenic tau (due to the shift into the RIPA- and FA-
fraction), in the RAB fraction, a higher degree of phosphorylation
was revealed for virtually all sites examined, suggesting that tau is
increasingly hyperphosphorylated in STZ-treated pR5 mice at 6
months of age (Figure 5A).
In conclusion, increased tau hyperphosphorylation in STZ-
treated pR5 mice is associated with early-onset tau deposition and
NFT formation.
Discussion
In the present study, we addressed whether metabolic changes
present in DM affect tau pathology, by inducing experimental DM
in a transgenic model of AD. Specifically, we showed that
depletion of insulin upon STZ injection and consequently,
chronically increased blood glucose levels causes hyperphosphor-
ylation of tau, a protein associated with AD. This treatment
accelerated tau pathology in pR5 mice, an established transgenic
strain prone to tau deposition and NFT formation [20]. In
particular, we found high levels of insoluble tau and numbers of
NFTs in the amygdala of 6 months-old STZ-treated pR5 mice
that are generally seen only in aged pR5 mice with an advanced
pathology [20,21]. Consistent with our previous findings [20,21], 6
months-old sham treated pR5 mice lacked an overt tau deposition
and had only very few NFTs in the amygdala, as appropriate for
this early stage of disease.
Other studies addressed tau phosphorylation in response to STZ
treatment, albeit in non-transgenic mice [18,19,28]. In these,
depletion of insulin resulted in a rapid increase in tau
phosphorylation three days post-injection of STZ [18] and in
progressively increasing levels of phosphorylated tau up to 40 days
post injection [19]. We observed similar increases in phosphory-
lation of endogenous tau in STZ-treated non-transgenic mice.
Interestingly, this was not associated with the formation of
insoluble tau aggregates or NFTs, suggesting that hyperpho-
sphorylation of tau upon insulin depletion in itself is not sufficient
Table 1. Details of tau specific antibodies used in this study.
name donor species epitope/specificity dilution source
HT7 mouse human tau 1:1000 WB Pierce
TAU5 mouse human and murine tau 1:1000 WB Chemicon
AT8 mouse Ser202/Thr205 1:1000 WB, 1:100 IHC Pierce
AT270 mouse Thr181 1:1000 WB Pierce
AT100 mouse Ser212/Thr214 1:1000 WB Pierce
12E8 mouse Ser262/Ser356 1:1000 WB Dr. Peter Seubert (Elan)
PHF-1 mouse Ser396/Ser404 1:1000 WB Dr. Peter Davies
PS422 rabbit Ser422 1:1000 WB, 1:200 IHC Biosource
WB, Western blotting; IHC, immunohistochemistry.
doi:10.1371/journal.pone.0007917.t001
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hyperphosphorylated tau were not high enough, or that there was
not sufficient time allowed to induce insoluble aggregates [29].
Increased tau phosphorylation in non-transgenic mice has also
been shown to be associated with decreased protein phosphatase
2A (PP2A) activity [18,19]. In addition, as insulin depletion causes
hypothermia, this may have contributed to the increased tau
phosphorylation at sites such as AT8 as was observed in non-
transgenic mice, since body temperatures drop after STZ injection
and warming the mice prior to isolating the brain partially reverses
phosphorylation [19]. Similarly, hypothermia induced by anes-
thesia increased tau pathology [30]. Furthermore, high glucose
levels in the brain, which are significantly increased already two
days after STZ administration, may contribute to the tau
pathology, since rapid glucose changes are known to affect brain
homeostasis. Taken together, decreased phosphatase activity,
hypothermia, as well as additional metabolic alterations due to
insulin deficiency and high brain glucose levels may contribute
concomitantly to the increased phosphorylation of tau in STZ-
Figure 3. Increased numbers of NFTs in STZ-treated pR5 mice.
Gallyas silver staining (black) of coronal section revealed abundant
numbers of flame-shaped NFTs and dystrophic neurites in the
amygdala of STZ-treated pR5 mice. In sham-injected pR5 mice, NFTs
were rare. No NFTs are found in sham- and STZ-injected wild-type (WT)
mice. Quantification of standardized serial sections showed 8-fold
increased numbers of NFTs in pR5 mice upon STZ-treatment (**,
P,0.001, n=6). Scale bar, 50 mm.
doi:10.1371/journal.pone.0007917.g003
Figure 2. Increased tau phosphorylation in STZ-treated pR5
mice. Immunohistochemistry with phosphorylation site-specific anti-
bodies reveals several AT8-positive neurons in the amygdala of sham-
injected pR5 mice at 6 months of age. Whereas in sham-injected pR5
mice most AT8-positive cells lack PS422 staining (open arrowhead),
there is a subset of neurons that also stains with PS422 (arrowhead).
Similarly, dystrophic neurites were AT8- but not PS422-positive in sham-
injected pR5 mice (inset). In contrast, upon STZ injection virtually all
tau-containing neurons (arrowhead), and dystrophic neurites (inset)
within the amygdala of pR5 mice stained with both AT8 and PS422, as
revealed by overlay (yellow). Quantification of AT8 and PS422 double
positive cells confirms significantly increased numbers of AT8/PS422
double positive in the amygdala of STZ-treated compared to sham-
injected pR5 mice (**, P,0.001; n=6). Scale bar, 50 mm.
doi:10.1371/journal.pone.0007917.g002
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remains to be elucidated.
In contrast to STZ-injected non-transgenic mice, increased
hyperphosphorylation of tau in insulin-depleted pR5 mice was
associated with abundant amounts of insoluble tau and 8-fold
increased formation of NFTs. In fact, the tau pathology of 6
months-old STZ-treated pR5 mice was accelerated as it was
comparable to that normally only found in pR5 mice above an age
of one year [20,21], or in pR5 mice intracerebrally injected with
aggregated Ab to exacerbate a pre-existing tau pathology [22].
Taken together, our findings suggest that a predisposition for tau
pathology, such as in young pR5 mice, is both sufficient and
necessary to induce tau insolubility and NFT formation in
experimental DM. This is consistent with the fact that in a wild-
type human tau transgenic mouse model that does not develop
NFTs despite high levels of phosphorylated tau [25], injection of
P301S mutant human tau can induce fibrilization and deposition
of non-mutant tau [31]. Hence, mutant human tau seems to
catalyze the formation of tau deposits in vivo, containing both
mutant and non-mutant tau [32,33]. While administration of STZ
in rodents reliably produces hyperglycemia due to destruction of
insulin secreting b-cells in pancreatic islets, other features of DM
are lacking, such as immunological aspects of type 1, or insulin-
resistance of type 2 diabetes [34]. Taken together, and keeping the
limitations of murine disease models in mind, our data suggests
that DM in humans can accelerate the progression of a pre-
existing tau pathology and exacerbate disease in patients that are
predisposed to develop tau pathology.
Figure 5. STZ-treatment induces hyperphosphorylation of tau
in pR5 and non-transgenic mice, but only in pR5 mice it
induced tau insolubility. (A) Amygdalae of STZ- or sham-injected
wild-type (WT) and pR5 mice were extracted with buffers of increasing
stringency and separated by SDS-PAGE for Western blotting. RAB
fractions contain soluble species of both transgenic human (triangle)
and endogenous murine (asterisk) tau, as shown with HT7 and TAU5,
respectively. Phosphorylation site-specific tau antibodies AT8, AT270,
AT100, 12E8, PHF-1 and PS422 (for details on antibodies see Table 1)
reveal increased phosphorylation of transgenic and endogenous tau at
multiple sites upon STZ-treatment. In sham-treated controls, tau is
slightly more phosphorylated in pR5 than WT mice. GAPDH confirmed
equal loading. (B) RIPA fractions of STZ-treated mice contain higher
amounts of both transgenic and endogenous tau than in sham-treated
controls. Actin confirmed equal loading. (C) Insoluble proteins were
extracted with formic acid (FA). In STZ-treated mice, HT7 and TAU5
show insoluble transgenic and endogenous tau, whereas no tau is
detectable in STZ-treated non-transgenic (WT) or sham-injected non-
transgenic and pR5 mice. (D) Extraction of sarkosyl-insoluble tau from
amygdala reveals significant amounts of sarkosyl-insoluble transgenic
human tau (HT7) were isolated from STZ-treated, but not sham-injected
pR5 mice.
doi:10.1371/journal.pone.0007917.g005
Figure 4. STZ administration does not affect transgene
expression levels and pattern. (A) Immunohistochemistry using
the human tau specific antibody HT7 reveals a similar expression
pattern in the amygdala of STZ-treated or sham-injected pR5 mice
(n=6). Scale bar, 50 mm. (B) Western blotting of protein extracts from
amygdala of STZ-treated or sham-injected pR5 mice (n=6) shows
comparable levels of transgenic human (triangle) and endogenous
murine (asterisk) tau, as detected by TAU5. GAPDH confirms equal
loading and was used to normalize TAU5 band intensities for
quantification.
doi:10.1371/journal.pone.0007917.g004
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accelerates onset and progression of tau pathology in tau
transgenic mice that are prone to NFT formation. Given the
high prevalence of DM and AD worldwide, with a significant
degree of co-morbidity, our finding may have direct pathomecha-
nistic implications in establishing a link between DM and AD.
Materials and Methods
Ethics Statement
All animal procedures have been approved by the University of
Sydney animal ethics authorities.
Mice
The generation of the pR5 mouse strain has been previously
described [20,35]. pR5 mice express the longest human tau
isoform carrying the pathogenic P301L mutation, under control of
the murine Thy1.2 promoter that drives neuronal expression of
the transgene. The mice were backcrossed and maintained on the
C57Bl/6J background.
Streptozotocin Treatment
Four months old pR5 mice and wild-type littermate controls
were injected i.p. with 200 mg/kg streptozotocin (STZ, Sigma,
USA) dissolved in 100 mM citrate buffer, pH 4.5. Controls were
injected with citrate buffer only. Mice were analyzed at 6 months
of age.
Blood Glucose and Insulin Measurements
Blood glucose levels were measured using a Freestyle Papillion
Mini (Abbott, Germany) from a 3 ml drop of blood obtained by
nicking the tail vein. Serum insulin levels were determined by
ELISA (Shibayagi, Japan).
Protein Extraction
Proteins of different solubility were extracted from brain in
buffers of increasing stringency, using a slightly modified protocol
previously described [24,25]. Briefly, brains were harvested and
the amygdala were dissected [36]. The tissues were weighed and
homogenized in 10 ml/mg RAB buffer (100 mM 2-(N-morpho-
lino) ethanesulphonic acid (MES; pH 7.0), 1 mM EDTA, 0.5 mM
MgSO4, 750 mM NaCl, 20 mM NaF, 1 mM Na3VO4 and
Complete protease inhibitors (Roche, Switzerland)) using a plastic
pistil (Eppendorf, Germany), followed by passing through a 29G
insulin needle (Terumo, USA). After 30 min of incubation on ice,
the samples were centrifuged at 50’0006g for 20 min at 4uC. The
supernatants containing RAB-soluble proteins were collected and
centrifuged again. The pellets from both spins were resuspended in
RAB buffer and centrifuged again. The supernatant was
discarded, the pellet resuspended in 7.5 ml/mg RIPA buffer
(50 mM Tris (pH 8.0), 150 mM NaCl, 1% NP40, 5 mM EDTA,
0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate) and
centrifuged at 50’0006g for 20 min at 4uC. The supernatants
containing RIPA-soluble proteins were collected and centrifuged
again. The pellets from both spins were resuspended in RIPA
buffer and centrifuged again. The supernatants were discarded
and the pellets were resuspended in 7.5 ml/mg 70% formic acid
(FA) in distilled water. Prior to centrifugation at 50’0006g for
20 min at 4uC, samples were incubated for 30 min on ice. The
supernatants containing FA-soluble proteins (also considered as
RIPA insoluble proteins) were centrifuged again. The FA fractions
were dialyzed against PBS over night at 4uC, then an equal
volume of 50 mM Tris-HCl, pH 7.4 was added to each sample.
Protein concentrations were determined using a DC Protein Assay
kit (BioRad, USA).
Furthermore, we extracted insoluble proteins from brains with
sarkosyl, following a method described previously [26,37]. Briefly,
hemispheres were weighed and homogenized in 6 ml/mg salt
buffer (100 mM MES (pH 6.8), 750 mM NaCl, 1 mM EGTA,
0.5 mM MgSO4, 1 mM dithriothreitol and protease inhibitors).
Homogenates were incubated for 20 min at 4uC and then
centrifuged at 11’0006g for 20 min at 4uC. The supernatant
was then centrifuged at 100’0006g for 60 min at 4uC. The
supernatant contained soluble proteins. For the isolation of
insoluble proteins, the pellets were twice extracted in 1:10 (w/v)
extraction buffer (10 mM Tris (pH 7.4), 10% sucrose, 850 mM
NaCl, 1 mM EGTA) and centrifuged at 15’0006g for 20 min at
4uC. The supernatants were combined and sarkosyl was added to
a final concentration of 1%, followed by 1 hour of incubation at
room temperature on a head-over-head rotor. The samples were
then centrifuged at 100’0006g for 45 min at 4uC to pellet the
sarkosyl-insoluble proteins, which were resuspended in 0.4 ml/mg
50 mM Tris-HCl, pH 7.4. All chemicals were obtained from
Sigma (USA), unless otherwise stated.
Western Blotting
Western blotting was carried out as previously described [38].
Briefly, proteins were separated by SDS-PAGE (Tetracell,
BioRad, USA) and electro-transferred onto nitrocellulose mem-
branes (Amersham, USA). The membranes were blocked with 5%
bovine serum albumin (BSA) in 50 mM Tris, pH 7.4, containing
0.1% Tween-20 for 1 hour at room temperature, before
incubation with primary antibodies in blocking buffer over night
at 4uC. Primary antibodies were against tau (Table 1), GAPDH
(Chemicon, USA) and actin (Sigma, USA). Bands were visualized,
using alkaline phosphatase-coupled secondary antibodies, together
with the Immobilon
TM Western substrate (Millipore, USA) in a
VersaDoc 4000 imaging system (BioRad, USA). Bands were
quantified with the Quantity One 1-D software v4.6 (BioRad,
USA).
Histology
Immunohistochemistry was carried out as previously described
[39,40]. Briefly, 4% paraformaldehyde (Sigma, USA) fixed tissue
from transcardially PBS perfused mice were embedded in paraffin
using an Excelsior tissue processor (Thermo, USA) and sectioned
at 5 mm. For standardization, all stainings were carried out in
Sequenza racks (Thermo, USA). Prior to blocking with PBS
containing 3% heat inactivated goat serum and 5% BSA for
1 hour at room temperature, antigen retrieval was performed in
10 mM citrate buffer, pH 5.8 in a RHS-1 microwave vacuum
histoprocessor (Milestone, USA) at 120uC. Sections were incubat-
ed over night at 4uC with primary antibodies in blocking buffer.
Primary antibodies were against tau targeting a range of epitopes
(Table 1), insulin and glucagon (both Sigma, USA). Antibody
staining was visualized using Alexa 555- and 488-coupled
secondary antibodies (Invitrogen, USA), together with nuclear
marking by 49,6-diamidino-2-phenylindole (DAPI, Invitrogen,
USA). Pictures were taken with a BX51 fluorescence microscope
equipped with a DP70 CCD color camera (Olympus, USA).
Gallyas silver staining to reveal NFTs was performed following a
standard protocol [27]. Hematoxylin/eosin staining was done
following standard protocol. For quantification of NFTs and
immunofluorescence, serial sections were stained and analyzed as
previously described [22].
DM Boosts Pathology in AD Mice
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